Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Return to V2 Home
Search
 
My Lists

Gilead Sciences  (Stock symbol: GILD )

333 Lakeside Drive
 Foster City, CA 94404
 USA
 (650)-574-3000
Website Company Summary Management Team
Management
CEO: Daniel O’Day (12/11/2018)
President/COO/Operations: Laura Hamill ; Anthony D Caracciolo (08/31/2003)
General Management: Diana Brainard (8/14/2018) ; John J Toole (08/31/2003); Seigo Izumo (09/11/2008) ; Taiyin Yang ; Clifford Samuel (07/31/2015) ; LeAnn Pipkins (10/31/2019) ; Linda S Higgins (12/1/2010) ; Bindu Garapaty (11/30/2018) ; Marc Berson (08/31/2020)
Finance: Andrew Dickinson (10/21/2019)
Technology: William A Lee
Sales/Marketing: Martin B Silverstein
General Counsel/Legal: Alexander D'Ull ; Brett Pletcher
Board
Outside board: (May no longer be on the board) Nicholas G Moore (PricewaterhouseCoopers Former Chairman) ;  John F Cogan (Stanford University Sr. Fellow) ;  John W Madigan (Tribune Company Former CEO/Chairman) ;  Carla Hills (Hills & Company CEO) ;  Richard Whitley (University of Alabama at Birmingham Professor) ;  Per Wold-Olsen (Merck & Co. Division President) ;  Sandra Horning (EQRx co-Founder) ;  Javier J Rodriguez (DaVita Kidney Care Former CEO) ;  Anthony Welters (UnitedHealth Group Sr. Adviser to the Office of the CEO) ;  Jeffrey A Bluestone (Sonoma BioTherapeutics CEO) ;  Etienne Davignon (Societe Generale de Belgique Vice Chairman) ;  James Denny (Sears Former CFO) ;  Gayle Edlund Wilson (Chela Financial) ;  Gordon Moore (Intel CHM Emeritus)
Former outside board: George P Shultz (Stanford University Fellow) ;  Paul Berg (Stanford University Professor) ;  James C Gaither (Cooley Godward Kronish);  Cordell Hull (InfrastructureWorld CEO);  H Dubose Montgomery (Menlo Ventures);  Don Rumsfeld (General Instruments CEO);  Benno Schmidt (J.H. Whitney)
Company
Business description: Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases worldwide. The company has five marketed products and focuses its research and clinical programs on anti-infectives, including antivirals, antifungals and antibacterials. Gilead today has seven marketed products and a clinical, preclinical and research pipeline focused on developing anti-infectives. We take great pride in our portfolio of unique therapeutics, which includes a number of category firsts and market leaders. The evolution of Gilead and our track record of success is testament to what the company has achieved through disciplined science, visionary thinking and diversified planning.
Partners include: Bristol-Myers Squibb ;  Chiron;  Globeimmune ;  Merck ;  Boehringer Ingelheim ;  DARPA;  Glaxo;  Hoffman-La Roche;  Tibotec Pharmaceuticals
Capital
Capital raised: 126.0M
Ownership: Public  
Stock Symbol: GILD
VCs include: Menlo Ventures;  Venrock Associates;  Chemical Venture Partners;  J.H. WhitneyAndCo.
Corporate investors: Glaxo

Last Tweets

 

Last Mentions

Overview
Record updated: Mar 2021
Sector: Biotech
Year Founded: 1987
Headcount: 10001-25000 as of Mar 2021
Capital Raised: 126.0M
Ownership: Public  
Stock Symbol: GILD
©2003-2022 Link Silicon Valley LLC Home